Organon (OGN) Asset Writedowns and Impairment (2021)

Organon (OGN) recorded quarterly Asset Writedowns and Impairment of $7.0 million in Q4 2021.

Organon (OGN) Asset Writedowns and Impairment (2021) Analysis & Trends

Organon's Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $7.0 million for Q4 2021.

In Q4 2021, Asset Writedowns and Impairment changed N/A year-over-year to $7.0 million; the TTM figure through Sep 2023 stood at $7.0 million (changed N/A YoY), while the FY2025 annual figure was $9.0 million, changed N/A from the prior year.
Asset Writedowns and Impairment was $7.0 million for Q4 2021 at Organon.
In the past five years, Asset Writedowns and Impairment ranged from a high of $7.0 million in Q4 2021 to a low of $7.0 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	93,026,132.38 Bn	93,026,127.42 Bn	7.76 Bn
2	Eli Lilly	1,022.62 Bn	1,017.34 Bn	16.22 Bn
3	Johnson & Johnson	570.65 Bn	548.59 Bn	15.96 Bn
4	AbbVie	398.73 Bn	389.38 Bn	10.78 Bn
5	Merck	295.53 Bn	289.88 Bn	12.09 Bn
6	Amgen	186.30 Bn	174.26 Bn	5.87 Bn
7	Gilead Sciences	155.93 Bn	148.21 Bn	5.52 Bn
8	Pfizer	146.09 Bn	133.32 Bn	-1.21 Bn
9	Bristol Myers Squibb	114.98 Bn	104.53 Bn	8.07 Bn
10	Organon	3.49 Bn	2.37 Bn	783.00 Mn

Download Data

Date	Value
Dec 31, 2021	7.00 Mn
Dec 31, 2021	7.00 Mn